Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts

scientific article published in November 2004

Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.TRIM.2004.06.002
P698PubMed publication ID15381205

P50authorTakashi MurakamiQ114083086
P2093author name stringMasafumi Takahashi
Eiji Kobayashi
Shin-ichi Takeda
Seiichiro Inoue
Takashi Kaneko
Izumi Takeyoshi
Yasuo Morishita
Hisashi Shimizu
Yoji Hakamata
Jun Fujishiro
P2860cites workConversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetilQ78225703
Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversionQ31750872
The use of mycophenolate mofetil in transplant recipientsQ33957200
Calcineurin inhibitors and post-transplant hyperlipidaemiasQ34417640
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategiesQ34503063
Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in miceQ37379247
Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro studyQ38525562
Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factorQ39760201
Chronic graft rejectionQ40573333
Hypertension after cardiac transplantation: pathophysiology and management.Q40947571
Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapyQ41184484
Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allograftsQ42555924
Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity.Q44039596
Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat.Q44289407
Effect of conversion from cyclosporine A to mizoribine on transplant arteriosclerosis in rat aortic allograft modelsQ44616856
Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients.Q54060063
LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2Q62619859
Cyclosporine-associated chronic nephropathyQ70376376
Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allograftsQ71410931
Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantationQ72648752
Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation?Q73152705
Host bone-marrow cells are a source of donor intimal smooth- muscle-like cells in murine aortic transplant arteriopathyQ73954861
Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: a preliminary reportQ74725306
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosisQ77859042
P433issue3
P921main subjectcyclosporineQ367700
P304page(s)219-227
P577publication date2004-11-01
P1433published inTransplant ImmunologyQ15758510
P1476titleConversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts
P478volume13

Reverse relations

cites work (P2860)
Q57839861Mycophenolate mofetil and animal models
Q36958317Mycophenolate mofetil and atherosclerosis: results of animal and human studies.
Q36544988Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability

Search more.